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Review
Iranian Blood Transfusion Organization (IBTO) is the sole 
organization providing blood services to hospitals and other 
medical centers throughout Iran, with a network of over 220 
blood centers in 31 provinces.
As a reference center, the immunohematology laboratory 
of the IBTO has been responsible for identifying and providing 
compatible blood for patients with rare blood types and for 
multiply transfused patients such as those with thalassemia 
who have developed several clinically important antibodies. 
Prior to 2009, IBTO used traditional non-systematic 
services when managing rare blood for these patients. However, 
to provide better service to donors and patients, IBTO decided 
to expand the operation of identifying rare blood donors and 
storing units of blood by developing the Iranian Rare Donor 
Program. This program expanded the management of rare 
blood to a systematic approach whereby the organization was 
prepared for any critical time when the request for rare blood 
was received for a patient with a difficult blood type.
History
The first initiative toward developing the Iranian Rare 
Donor Program was triggered through a collaborative program 
called the Joint Program Review and Planning Mission (JPRM 
2008–2009) between the World Health Organization (WHO) 
and IBTO with a goal to increase blood safety in Iran. Available 
resources were studied and the absence of processes and 
deficiencies in provided services were identified and analyzed.
We also contacted international organizations that were 
already experienced in rare donor activities. In this endeavor, 
contact was initiated between IBTO and the International 
Blood Group Reference Laboratory (IBGRL-WHO) in Bristol, 
UK, to learn from their experience and to receive their support. 
IBTO was interested in a longstanding collaboration with 
IBGRL-WHO.
Dr. G. Woodfield (past chair of the International Society of 
Blood Transfusion [ISBT] Working Party on Rare Donors) was 
kind enough to accept IBTO’s invitation to travel to Tehran in 
2010 to share his scientific knowledge and technical expertise 
through a series of lectures in a 2-week workshop.
Responsible heads of the IBTO’s special serology 
laboratories attended the workshop. They were selected to 
be the future technical specialists who would participate in 
the national rare donor program. The goal was to review the 
approaches that would help in the establishment of a systematic 
and successful national rare donor program.
Other issues that needed close attention were designing 
the complete structure of the rare donor program, finding the 
correct approach to screening blood donors to identify rare red 
blood cell (RBC) phenotypes for the program’s data registry, 
and deciding on the number of donors to be screened in a 
specific period of time.
National Rare Donor Database
To meet the requests of patients with rare blood types, 
IBTO decided to regularly screen blood donor samples received 
randomly from selected blood centers in 31 provinces at the 
Immunohematology Reference Laboratory in Tehran for rare 
blood types. Populations from these provinces are ethnically 
and geographically diverse. Today, more than 35,000 blood 
samples have been phenotyped serologically. The initial 
antigens screened are in the Rh (C, e, E, c), Kell (K, k), Duffy 
(Fya, Fyb), Kidd (Jka, Jkb), and MNS (S, s) systems. All blood 
samples are selected from group O blood donors.
The National Rare Donor Database currently consists 
of information from approximately 1000 active rare donors 
divided into two groups; this process was adopted from a 
review article published in Immunohematology.1 Group I (rare 
donors) are defined as those negative for multiple common 
antigens (428 new donors added in 2012–2014) and Group 
II (very rare donors) are defined as those negative for a high-
prevalence antigen (72 new donors added in 2012–2014). 
The inventory of very rare units currently consists of about 
170 frozen RBC units stored at –80°C (Table 1). The national 
database also includes two Rhnull donors and two K0 donors. 
Their molecular backgrounds have yet to be identified.
Where Are We Now?
In 2015, the Iranian Rare Donor Program is a well-
established service in IBTO. Between 2012 and 2014, a total of 
93 rare units were shipped domestically to medical centers in 
the country, with 2 requests not filled. One request was for a 
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26-year-old labor and delivery patient from Ilam province with 
an antibody against an unknown high-prevalence antigen. 
The second request was for a 28-year-old male thalassemia 
intermediate patient with antibody of unknown specificity. 
There were also three incompatible transfusion cases. 
All three patients were suffering from beta thalassemia 
intermediate disorder. One patient was identified as having 
warm autoimmune hemolytic anemia. Because blood trans-
fusion was not helpful and due to extramedullary hematopoiesis, 
intravenous steroids and radiotherapy were started with good 
outcome. The other two patients were identified with multiple 
antibodies including anti-E, -c, -M, -Jka, and an antibody 
of unknown specificity. The patient with anti-M and -Jka 
experienced a severe hemolytic transfusion reaction and died 
due to the transfusion of multiple incompatible RBC units.
In general, the practice in Iran has been to use oral 
promethazine, diphenhydramine, and hydrocortisone as 
prophylaxis prior to RBC transfusion to a patient with a history 
of transfusion reactions rather than referring the patient’s 
sample to an immunohematology reference laboratory to 
identify the antibody and provide antigen-negative blood. 
With the establishment of the Iranian Rare Donor Program, 
we hope to see this practice eliminated. 
Encouraging Rare Donors
Personal appreciation, educational materials, and occa-
sionally gift cards of no more than a $20 value, to compensate 
for donor time off from work or transportation expenses, are 
offered as incentives to encourage awareness and willingness 
among donors to collaborate with the program.
Every year, January 11th is celebrated as National Rare 
Donor Day in Iran for rare donor recognition and is attended 
by officials from the Ministry of Health and IBTO’s higher 
management; the activities are covered by the national media.2
After joining the ISBT Working Party on Rare Donors 
in 2010, our goal has been for Iran to be one of the active 
members of the committee. It is currently the only country 
from the Eastern Mediterranean Region in the Working 
Party. For the first time in September 2014, IBTO organized 
an international meeting on rare donors supported by the 
ISBT Academy. International speakers and participants from 
Europe, Asia, New Zealand, Africa, and the Middle East 
attended the meeting.
IBTO is potentially ready to fill orders and ship rare units 
for international requests, particularly to meet requests from 
neighboring countries.
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Table 1. Identified donors and current inventory of very rare blood 
in Iran as of 2014
Phenotype
Number of donors
Frozen RBC units stored at –80°C*2012 2014
Oh (Bombay) 32 10 26
Fy(a–b–) 14 22 12
Lu(a–b–) 3 5 10
r´r´ 1 9 10
k– 4 5 9
D– – 3 3 8
RzR1 7 10 5
r''r'' 2 0 3
Kp(b–) 1 0 2
RzR2 1 2 2
RzRz 0 2 1
K0 0 2 1
Rhnull 0 2 0
*RBC = red blood cell.
